Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Globus Medical Inc (NYSE: GMED) closed at $87.75 down -1.44% from its previous closing price of $89.03. In other words, the price has decreased by -$1.44 from its previous closing price. On the day, 2.04 million shares were traded. GMED stock price reached its highest trading level at $90.26 during the session, while it also had its lowest trading level at $87.7.
Ratios:
For a deeper understanding of Globus Medical Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 30.25 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.38. For the most recent quarter (mrq), Quick Ratio is recorded 2.47 and its Current Ratio is at 4.13. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
On November 07, 2025, BofA Securities Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $91.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 01 ’25 when Kline Kyle sold 18,542 shares for $90.00 per share. The transaction valued at 1,668,780 led to the insider holds 0 shares of the business.
Kline Kyle bought 18,542 shares of GMED for $1,667,847 on Dec 01 ’25. On Nov 25 ’25, another insider, Huller Kelly, who serves as the SVP, GC, Corporate Secretary of the company, sold 7,500 shares for $90.00 each. As a result, the insider received 675,000 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GMED now has a Market Capitalization of 11851273216 and an Enterprise Value of 11473977344. As of this moment, Globus’s Price-to-Earnings (P/E) ratio for their current fiscal year is 28.36, and their Forward P/E ratio for the next fiscal year is 21.78. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.36. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.26 while its Price-to-Book (P/B) ratio in mrq is 2.69. Its current Enterprise Value per Revenue stands at 4.143 whereas that against EBITDA is 14.349.
Stock Price History:
The Beta on a monthly basis for GMED is 1.07, which has changed by 0.07148874 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, GMED has reached a high of $94.93, while it has fallen to a 52-week low of $51.79. The 50-Day Moving Average of the stock is 26.55%, while the 200-Day Moving Average is calculated to be 34.10%.
Shares Statistics:
For the past three months, GMED has traded an average of 1.68M shares per day and 1719200 over the past ten days. A total of 112.18M shares are outstanding, with a floating share count of 111.38M. Insiders hold about 17.25% of the company’s shares, while institutions hold 88.23% stake in the company. Shares short for GMED as of 1763078400 were 4824835 with a Short Ratio of 2.87, compared to 1760486400 on 6331670. Therefore, it implies a Short% of Shares Outstanding of 4824835 and a Short% of Float of 4.8600003.
Earnings Estimates
The stock of Globus Medical Inc (GMED) is currently drawing attention from 12.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $0.89, with high estimates of $0.98 and low estimates of $0.79.
Analysts are recommending an EPS of between $3.81 and $3.76 for the fiscal current year, implying an average EPS of $3.79. EPS for the following year is $4.11, with 12.0 analysts recommending between $4.3 and $3.85.
Revenue Estimates
A total of 11 analysts believe the company’s revenue will be $777.51M this quarter.It ranges from a high estimate of $788.6M to a low estimate of $767.5M. As of. The current estimate, Globus Medical Inc’s year-ago sales were $657.29MFor the next quarter, 11 analysts are estimating revenue of $726.05M. There is a high estimate of $749.8M for the next quarter, whereas the lowest estimate is $698.93M.
A total of 11 analysts have provided revenue estimates for GMED’s current fiscal year. The highest revenue estimate was $2.9B, while the lowest revenue estimate was $2.88B, resulting in an average revenue estimate of $2.89B. In the same quarter a year ago, actual revenue was $2.52BBased on 12 analysts’ estimates, the company’s revenue will be $3.11B in the next fiscal year. The high estimate is $3.16B and the low estimate is $3.05B.
